Alexander Pickett

Bio:

Alexander Pickett is Managing Director at Juvenescence, where he oversees new opportunity onboarding. He has worked with Juvenescence’s founding partners at Mediqventures, Ltd., a multi-family investment partnership and merchant bank, where he supported existing investments at Portage Biotech Inc., including Portage Pharma Ltd. and Biohaven (NYSE:BHVN). Alexander was on the founding team of SalvaRx Limited, a cancer immunotherapy-focused investment company that was later merged into Portage Biotech. Alexander is also an investor in Lila. Juvenescence was one of the first big investors in In Silico Medicine and incubated Relation Therapeutics. They are also provided seed financing for Morphoceuticals, an AI enabled company focused on white space in biology. Prior to joining Mediqventures, Alexander was an associate at Flatley Venture Capital, a cystic fibrosis-focused investment arm of the John J. Flatley Company, where he was responsible for investment analysis and scientific due diligence.